AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$CADL

Tyagarajan Seshu sold $84K of CADL

Tyagarajan Seshu (Chief Technology Officer) sold 7,000 shares of Candel Therapeutics, Inc. (CADL) at $12.00 on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tyagarajan Seshu
Published Aug 19, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CADL
Neutral
high confidence
Mentioned
$CADL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CADLNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering little new trading insight.

02

Market read

Limited relevance; typical insider sale with minimal market effect.

03

Timing

post‑market 2026-08-17 filing

Relevance 2/10Novelty 4/10Timing: post‑market 2026-08-17 filing

Background

SEC Form 4 filing reports insider transaction for Candel Therapeutics (CADL).

Company-level read

Ticker impact

$CADLNeutralHigh confidence
Context

Form 4 disclosed CTO sold 7,000 shares for $84K via 10b5-1 plan on 2026-08-17.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical for pre‑arranged plans.

Market effects

Sector

none

Regional

none

Global

none

Key entities

  • company
    Candel Therapeutics, Inc.

    Biotech firm listed on NASDAQ under CADL.

  • person
    Tyagarajan Seshu

    Chief Technology Officer of CADL.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CADL insider trading history →

Related articles

OCT 1
$CADLMedAI 8/10

Candel's Aglatimagene Shows Prolonged Survival In Phase 2a NSCLC Trial

Candel Therapeutics (CADL) reported Phase 2a trial results for aglatimagene in NSCLC patients. Median overall survival was 24.5 months in the evaluable population. The treatment showed systemic immune responses and was generally well tolerated. Candel is advancing to a Phase 3 trial. CADL stock is currently at $10.39, down 0.67%.

rttnews.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.

globenewswire.com2 min
SEP 21
$CADLHigh

Why is Candel Therapeutics stock surging today?

Candel Therapeutics (CADL) stock rose 7.2% to $11.63 after Bank of America upgraded it to Buy with an $18.00 price target, up from $12.00. The company has 8 Buy ratings, 1 Hold, and no Sell recommendations. Its lead therapy targets a $10–16B prostate cancer market. The Nasdaq and S&P 500 also gained 1.1% and 0.7%, respectively.

investing.com1 min